European marketing authorizations for Timentin®

admin2022-01-14T14:49:53+00:00August 3rd, 2020|

Availability of XYLLOMAC® 1g, powder for solution for injection/IM-IV infusion, box of 1, in pharmacies 13/12/2023
Commercialisation of LORAZEPAM XILMAC® 4mg/ml, solution for injection, in France 06/11/2023
Availability of Ceplene® 0.5mg/0.5ml, solution for injection (Histamine dihydrochloride), in Germany and Austria 09/10/2023
Availability of Prostaphlin® 1000 mg for Czech market 26/01/2023
Commercialization of amoxicilline in Ireland 16/01/2023
THE LABORATOIRES DELBERT ANNOUNCES A SERVICES AGREEMENT WITH IBI 30/11/2022
Acquisition de TERALITHE® par les Laboratoires Delbert 05/07/2022
Acquisition of TERALITHE® by the Laboratoires Delbert 17/05/2022
Laboratoires Delbert – Help to Ukraine 14/04/2022
Augmentin® injectable devient Levmentin® : informations et dates de mise à disposition 07/03/2022

49, rue Rouelle
75015 Paris
France
Phone + 33 1 46 99 68 20

By continuing to browse, you accept the use of third-party services that may install cookiesOK No privacy policy